Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Stock Information for Adagene Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Adagene Inc.

Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference
Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar
Genenta Announces Euro20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates
TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE
Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing
ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE
Genenta's CEO to present at the U.S. Senate meeting on "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective"

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.